A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex.
Iris E OverwaterAndré B RietmanSabine E MousKaren G C B Bindels-de HeusDimitris RizopoulosLeontine W Ten HoopenThijs van der VaartFloor E JansenYpe ElgersmaHenriette A MollMarie-Claire Y de Witnull nullPublished in: Neurology (2019)
This study provides Class I evidence that for children with TSC, everolimus does not improve intellectual disability, autism, behavioral problems, or other neuropsychological deficits.